Cardiovascular diseases are among top dreadful diseases and leading cause of death and disability worldwide. Largely, these diseases are polygenic with environmental contributions. Last fifty years of research on cardiovascular diseases has guided us to recognize modifiable and non-modifiable risk factors having clinical relevance. Some scientists have utilized molecular markers and imaging techniques for identifying preclinical phase of cardiovascular disorders. But despite all this knowledge, individual variations of genes and genetic variants have perplexed us to pinpoint causes, concomitants and consequences of cardiovascular pathology.
Panoply of research including whole genome and exome sequencing on cardiovascular diseases has guided us to focus on personalized management of these disorders. Personalized or precision medicine involves integrated approach of genomics, proteomics and nanotechnology along with step wise identification of molecular pathways for devising risk scores of every individual suffering from these diseases. On the basis of these individualized polygenic risk scores, degree of susceptibility is noted down for further intervention. American Heart Association has recommended genetic testing for every patient having cardiovascular disease such as cardiomyopathies, arrythymias, peripheral and cerebral vascular diseases as well as hypercholesterolemia. American College of Medical Genetics has also suggested some pertinent and actionable genes for the management of cardiovascular disorders. In the last couple of years, cardiovascular genetics has heralded new avenues and possibilities in the direction of prognostics, diagnostics and therapeutics. Warfarin dosing based on individual testing for CYP2C9 and VKORC1 genes recommended in these conditions is an important lesson to learn. A research on genetic mutations in LDL-R gene causing familial hypercholesterolemia fetched a Nobel Prize in 1985. Apropos to the plenitude contributions of genetics in the service of cardiovascular disease management, this special issue intends to bring together some insightful leads on those molecular culprits which participate but are still absconding from the scenes of cardiovascular diseases, posing consistent fear and threat to our population.
Dr. Sarabjit Mastana and Dr. Puneetpal Singh
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.
- Trafficking and Gating Cooperation Between Deficient Nav1.5-mutant Channels to Rescue INaJérôme Clatot, Alain Coulombe, Isabelle Deschênes, Pascale Guicheney, Nathalie NeyroudFront. Biosci. (Landmark Ed) 2022, 27(7), 209; https://doi.org/10.31083/j.fbl2707209(This article belongs to the Special Issue Genetics of Cardiovascular Diseases)56Download208Views